Overview

COMT on Aspirin Platelets Effects (CAPE)

Status:
Recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

Specific Aim I: Examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and ADP. Specific Aim II: Examine the effects of platelet releasates harvested at the end of each treatment arm on angiogenesis.

Phase:

Phase 4

Details

Lead Sponsor:

Brigham and Women's Hospital

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Aspirin